SCA
CHRS icon

Secor Capital Advisors’s Coherus Oncology CHRS Stock Holding History

Secor Capital Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-21,703
Closed -$196K – 428
2018
Q4 		$196K Sell
21,703
-64,379
-75% -$745K 0.03% 419
2018
Q3 		$1.42M Buy
+86,082
New +$1.53M 0.15% 207
2017
Q4 		– Sell
-25,365
Closed -$339K – 497
2017
Q3 		$339K Buy
25,365
+5,842
+30% +$77.3K 0.03% 374
2017
Q2 		$280K Buy
+19,523
New +$376K 0.03% 403

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Secor Capital Advisors's CHRS Position: Q1 2019 in Review

Secor Capital Advisors sold out of Coherus Oncology (CHRS) in Q1 2019, closing a stake of 21,703 shares — an estimated $196K sold.

Secor Capital Advisors first reported a position in CHRS in Q2 2017 and held it in 4 quarters. The position peaked at $1.42M in Q3 2018. 117 funds tracked by Wall St. Rank hold CHRS as of Q1 2019.

  • Secor Capital Advisors reported no remaining Coherus Oncology position as of Q1 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 21,703 Coherus Oncology shares in Q1 2019, an estimated $196K.
  • Secor Capital Advisors first reported a position in Coherus Oncology in Q2 2017 and held it in 4 quarters.
  • Secor Capital Advisors's Coherus Oncology position peaked at $1.42M in Q3 2018.
  • 117 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.